Drug Trial Radar · NCT02268253
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Last checked: Nov 20, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Feb 10, 2016
Primary completion
Mar 27, 2023
Study completion Mar 27, 2023
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, multi-arm trial evaluated the safety and efficacy of tagraxofusp, a cell division cycle protein 123 homolog-targeted therapy, in participants with either CMML or MF. There were 2 CMML cohorts, 1 enrolled participant with CMML (CMML-1 or CMML-2) who were refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy and 1 enrolled treatment-naive participants with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort enrolled participants who were resistant/refractory or intolerant to approved Janus kinase (JAK) therapy (JAK1/JAK2 or JAK2).
Conditions
- Myelofibrosis
- Chronic Myelomonocytic Leukemia
Interventions
Tagraxofusp InjectionDrug
Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: 21 days of Cycle 1 (21 days/cycle)
- Objective Response Rate (ORR)Time frame: 1145 days
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Francisco
Clovis, California
City of Hope
Duarte, California
University of California, Los Angeles
Los Angeles, California
Stanford Cancer Institute
Stanford, California
Mayo Clinic Florida
Jacksonville, Florida
Georgia Cancer Center at Augusta University
Augusta, Georgia
Rush University Medical Center
Chicago, Illinois
Indiana Blood and Bone Marrow Transplantation
Indianapolis, Indiana
University of Kansas Cancer Center
Westwood, Kansas
Norton Cancer Institute
Louisville, Kentucky
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
John Theurer Cancer Center
Hackensack, New Jersey
University of New Mexico
Albuquerque, New Mexico
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medical Center
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University of Alberta
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.